LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens ...

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...

Eli Lilly and Co. has received the U.S. Food and Drug Administration’s breakthrough therapy designation for a drug in development to treat certain ovarian cancer patients. The Indianapolis-based ...

Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to be presented as a late-breaking oral ...

By Arasu Kannagi Basil Jan 7 (Reuters) - Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized initial public offering, signaling ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy and hold for 20 years. On January 20, 2026, Guggenheim ...

The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal ...

Aktis Oncology (AKTS) stock surged after an upsized Nasdaq IPO aimed at raising ~$318M with the help of its partner Eli Lilly (LLY). Read more here.

Aktis Oncology Inc. increased the size of its initial public offering by 50%, and drew interest from Indianapolis-based Eli Lilly and Co. for $100 million of shares in the listing. The clinical-stage ...

Duarte, Calif.-based City of Hope and Eli Lilly have partnered on an oncology-based pharmacy residency program. Wafa Samara, PharmD, vice president and chief pharmacy officer at City of Hope, shared ...

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough ...